Literature DB >> 23814263

Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.

Mark Vitucci1, Natalie O Karpinich, Ryan E Bash, Andrea M Werneke, Ralf S Schmid, Kristen K White, Robert S McNeill, Byron Huff, Sophie Wang, Terry Van Dyke, C Ryan Miller.   

Abstract

BACKGROUND: Glioblastoma (GBM) genomes feature recurrent genetic alterations that dysregulate core intracellular signaling pathways, including the G1/S cell cycle checkpoint and the MAPK and PI3K effector arms of receptor tyrosine kinase (RTK) signaling. Elucidation of the phenotypic consequences of activated RTK effectors is required for the design of effective therapeutic and diagnostic strategies.
METHODS: Genetically defined, G1/S checkpoint-defective cortical murine astrocytes with constitutively active Kras and/or Pten deletion mutations were used to systematically investigate the individual and combined roles of these 2 RTK signaling effectors in phenotypic hallmarks of glioblastoma pathogenesis, including growth, migration, and invasion in vitro. A novel syngeneic orthotopic allograft model system was used to examine in vivo tumorigenesis.
RESULTS: Constitutively active Kras and/or Pten deletion mutations activated both MAPK and PI3K signaling. Their combination led to maximal growth, migration, and invasion of G1/S-defective astrocytes in vitro and produced progenitor-like transcriptomal profiles that mimic human proneural GBM. Activation of both RTK effector arms was required for in vivo tumorigenesis and produced highly invasive, proneural-like GBM.
CONCLUSIONS: These results suggest that cortical astrocytes can be transformed into GBM and that combined dysregulation of MAPK and PI3K signaling revert G1/S-defective astrocytes to a primitive gene expression state. This genetically-defined, immunocompetent model of proneural GBM will be useful for preclinical development of MAPK/PI3K-targeted, subtype-specific therapies.

Entities:  

Keywords:  Pten; astrocytes; genetically engineered mouse; glioblastoma; invasion

Mesh:

Substances:

Year:  2013        PMID: 23814263      PMCID: PMC3779038          DOI: 10.1093/neuonc/not084

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  46 in total

Review 1.  The multiple roles of PTEN in tumor suppression.

Authors:  A Di Cristofano; P P Pandolfi
Journal:  Cell       Date:  2000-02-18       Impact factor: 41.582

2.  Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions.

Authors:  J H Dannenberg; A van Rossum; L Schuijff; H te Riele
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

3.  Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis.

Authors:  Caroline Gregorian; Jonathan Nakashima; Janel Le Belle; John Ohab; Rachel Kim; Annie Liu; Kate Barzan Smith; Matthias Groszer; A Denise Garcia; Michael V Sofroniew; S Thomas Carmichael; Harley I Kornblum; Xin Liu; Hong Wu
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

4.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

5.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

6.  U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line.

Authors:  Michael James Clark; Nils Homer; Brian D O'Connor; Zugen Chen; Ascia Eskin; Hane Lee; Barry Merriman; Stanley F Nelson
Journal:  PLoS Genet       Date:  2010-01-29       Impact factor: 5.917

7.  Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.

Authors:  Yunqing Li; Fadila Guessous; Charles DiPierro; Ying Zhang; Tucker Mudrick; Lauren Fuller; Elizabeth Johnson; Lukasz Marcinkiewicz; Matthew Engelhardt; Benjamin Kefas; David Schiff; Jin Kim; Roger Abounader
Journal:  Mol Cancer Ther       Date:  2009-02-03       Impact factor: 6.261

8.  Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.

Authors:  H J Jun; J Acquaviva; D Chi; J Lessard; H Zhu; S Woolfenden; R T Bronson; R Pfannl; F White; D E Housman; L Iyer; C A Whittaker; A Boskovitz; A Raval; A Charest
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

9.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

10.  Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.

Authors:  Cameron Brennan; Hiroyuki Momota; Dolores Hambardzumyan; Tatsuya Ozawa; Adesh Tandon; Alicia Pedraza; Eric Holland
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

View more
  28 in total

1.  Collective invasion of glioma cells through OCT1 signalling and interaction with reactive astrocytes after surgery.

Authors:  Yangjin Kim; Donggu Lee; Sean Lawler
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-07-27       Impact factor: 6.237

2.  Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling.

Authors:  Xinya Gao; Xin Xia; Fanying Li; Maolei Zhang; Huangkai Zhou; Xujia Wu; Jian Zhong; Zheng Zhao; Kun Zhao; Dawei Liu; Feizhe Xiao; Qiang Xu; Tao Jiang; Bo Li; Shi-Yuan Cheng; Nu Zhang
Journal:  Nat Cell Biol       Date:  2021-03-04       Impact factor: 28.824

Review 3.  Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.

Authors:  Fawz S AlHarthi; Alya Qari; Alaa Edress; Malak Abedalthagafi
Journal:  NPJ Genom Med       Date:  2020-02-03       Impact factor: 8.617

Review 4.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

5.  Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma.

Authors:  Pravin Kesarwani; Antony Prabhu; Shiva Kant; Prakash Chinnaiyan
Journal:  Cancer Immunol Immunother       Date:  2019-05-22       Impact factor: 6.968

6.  Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.

Authors:  Robert S McNeill; Ralf S Schmid; Ryan E Bash; Mark Vitucci; Kristen K White; Andrea M Werneke; Brian H Constance; Byron Huff; C Ryan Miller
Journal:  J Vis Exp       Date:  2014-08-12       Impact factor: 1.355

7.  Expression Profiling of the MAP Kinase Phosphatase Family Reveals a Role for DUSP1 in the Glioblastoma Stem Cell Niche.

Authors:  Bradley N Mills; George P Albert; Marc W Halterman
Journal:  Cancer Microenviron       Date:  2017-08-18

8.  Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.

Authors:  Onyinyechukwu Okolie; Juli R Bago; Ralf S Schmid; David M Irvin; Ryan E Bash; C Ryan Miller; Shawn D Hingtgen
Journal:  Neuro Oncol       Date:  2016-06-13       Impact factor: 12.300

9.  Myocyte enhancer factor 2D promotes tumorigenicity in malignant glioma cells.

Authors:  Youguang Zhao; Ying Li; Yuan Ma; Songtao Wang; Jingmin Cheng; Tao Yang; Zhiyong Sun; Yongqin Kuang; Haidong Huang; Kexia Fan; Jianwen Gu
Journal:  Tumour Biol       Date:  2015-08-04

Review 10.  Contemporary murine models in preclinical astrocytoma drug development.

Authors:  Robert S McNeill; Mark Vitucci; Jing Wu; C Ryan Miller
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.